Objective-Carboxyl terminal truncation of apolipoprotein (apo)B-100 and apoB-48 impairs their capacity for triglyceride transport, but the ability of the resultant truncated apoB to transport cholesterol and to support atherosclerosis has not been adequately studied. The atherogenicity of apoB-38.9 was determined in this study by using our apoB-38.9 -only (Apob 38.9/38.9 ) mice. Methods and Results-ApoB-38.9-lipoproteins (Lp-B38.9) circulate at very low levels in Apob 38.9/38.9 mice as small LDLs or HDLs. Disruption of apoE gene in these mice caused accumulation of large amounts of ␤VLDL-like LpB-38.9 in plasma. These ␤VLDL particles were more enriched with cholesteryl esters but poor in triglycerides compared with the apoB-48-␤VLDL of the apoB-wild-type/apoE-null (Apob ϩ/ϩ /Apoe Ϫ/Ϫ ) mice. Likewise, apoB-38.9-VLDL secreted by cultured Apob 38.9/38.9 mouse hepatocytes also had higher ratios of total cholesterol to triglycerides than apoB-48-VLDL secreted by the apoB-48 -only hepatocytes. Thus, despite its impaired triglyceride-transporting capacity, apoB-38.9 has a relatively intact capacity for cholesterol transport. Spontaneous aortic atherosclerotic lesions were examined in apoB-38.9 -only/apoE-null (Apob 38.9/38.9 /Apoe Ϫ/Ϫ ) mice at ages 9 and 13 months. It plays a central role in lipid transport throughout the body. In addition to its normal lipid-transport functions, apoB is the major atherogenic apolipoprotein in humans and experimental animals. [3] [4] [5] High levels of plasma apoBcontaining lipoproteins are a well-established causal factor for the development of atherosclerotic diseases. 3-5 Therefore, it is important to understand fully the structure-function relationship of apoB.
A polipoprotein (apo)B 1 is an indispensable structural protein component of the triglyceride-rich VLDLs secreted by the liver and the chylomicrons secreted by the intestine. 1, 2 It plays a central role in lipid transport throughout the body. In addition to its normal lipid-transport functions, apoB is the major atherogenic apolipoprotein in humans and experimental animals. [3] [4] [5] High levels of plasma apoBcontaining lipoproteins are a well-established causal factor for the development of atherosclerotic diseases. [3] [4] [5] Therefore, it is important to understand fully the structure-function relationship of apoB.
The full-length apoB (apoB-100) contains 4536 amino acid residues 1,2 that are predicted to form a pentapartite structure composed of 3 amphipathic ␣-helical domains alternating with 2 ␤-strand domains. 6, 7 Because of a post-transcriptional modification of the apoB mRNA that converts codon 2153, CAA, to a stop codon, UAA, the apoB protein also exists in a truncated form containing the NH 2 terminal 48% of apoB-100, designated apoB-48. 8, 9 In humans, apoB-48 is produced only by the intestine, 1, 10 whereas both the intestine and the liver in rodents secrete apoB-48. 11, 12 Thus, although apoB-100 is the predominant apoB isoform in human plasma, 1, 2 apoB-100 and apoB-48 circulate in mice at similar levels. 11, 12 In addition to the normal apoB isoforms, numerous forms of COOH terminally truncated apoB, with sizes ranging from apoB-27.6 to apoB-89, have been identified in the plasma of humans with familial hypobetalipoproteinemia (FHBL). 2, 13, 14 They are the products of nonsense and frameshift mutations in the apoB gene (Apob) that result in the formation of premature termination codons. 2, 13, 14 These naturally occurring apoB genetic variants have provided valuable information on the structure-function relationship of apoB. For example, we demonstrated in vivo that COOH terminal truncation of apoB-100 and apoB-48 impairs their capability for triglyceride transport, [15] [16] [17] [18] resulting in accumulation of triglycerides in the liver of FHBL humans 16,19 -21 and mice. 17, 18 We and other investigators have also shown that the truncated apoB-containing lipoproteins are cleared rapidly from the plasma because of their enhanced interactions with the LDL receptor-mediated pathway [22] [23] [24] and/or with an LDL receptor-independent megalin-mediated pathway. 25, 26 In contrast, little is known about the correlation between the size of an apoB variant and its ability to support atherogenesis. Nevertheless, the critical structural domains of apoB that are essential for the atherogenicity of apoB-containing lipoproteins may be located within the NH 2 terminal 48% of the apoB-100 because apoB-48 and apoB-100 appear to be equally atherogenic. 27 Thus, it is particularly interesting and important to understand the function of those truncated apoB variants that are smaller than apoB-48 in cholesterol transport and atherogenesis. Such studies may lead to elucidation of the relationship between the apoB structure and the atherogenicity of apoB-containing lipoproteins. Unfortunately, FHBL subjects are not suitable models to address this issue because subjects homozygous for an apoB truncation mutation are very rare. 13, 14 Recently, we created a mouse bearing a knocked-in single base pair deletion on its Apob at the position identical to that of a naturally occurring apoB-38.9 mutation in an FHBL kindred. 17 This mouse may be a valuable animal model to define the atherogenicity of apoB-38.9 -containing lipoproteins. Our previous studies demonstrated that apoB-38.9 has an impaired capacity for hepatic triglyceride transport, 17, 18 but its ability to form cholesterol-rich atherogenic lipoprotein particles is unknown. Thus, in the present study, we used this mouse to address the following two questions: Does apoB-38.9 also have an impaired cholesterol-transporting capacity? Do the apoB-38.9 -containing lipoproteins promote atherosclerosis? To examine the capacity of apoB-38.9 for cholesterol transport, we assessed whether cholesterol-rich VLDLsized apoB-38.9 -containing lipoproteins accumulate in the plasma of apoB-38.9 -only/apoE-null (Apob 38.9/38.9 /Apoe Ϫ/Ϫ ) mice. We also determined the lipid composition of the newly secreted apoB-38.9 -VLDL. To assess the atherogenic potential of apoB-38.9 -containing lipoproteins, we quantified spontaneous aortic atherosclerotic lesions in Apob 38.9/38.9 / Apoe Ϫ/Ϫ mice. These studies establish the ability of apoB-38.9 to form cholesterol-rich lipoproteins and support atherosclerosis.
Methods

Mice
The apoB-38.9 mice have been described previously. 17 They were produced with mouse embryonic stem cell technology by using conventional homologous recombination and Cre-loxp system. 17 They have a mixed genetic background with 50% C57BL/6 and 50% 129/SvJ. ApoE-null mice 28 were from The Jackson Laboratory (Bar Harbor, ME) and had a C57BL/6 background. Thus, offspring from crossbreeding of the apoB-38.9 mice with these apoE-null mice had a mixed genetic background with 75% C57BL/6 and 25% 129/SvJ. In some experiments, we also used apoB-48 -only mice 29 (The Jackson Laboratory) to isolate hepatocytes. They have a mixed genetic background with 50% C57BL/6 and 50% 129/SvJ. All mice were weaned at 3 weeks of age, housed in a specific pathogen-free barrier facility with a 12-hour light/ dark cycle, and fed a regular mouse chow diet (Ralston Purina, St. Louis, MO).
Western Blot Detection of ApoB and Lipoprotein Fractionation
To perform Western blot analysis, aliquots of mouse plasma were subjected to electrophoresis on 3% to 12% gradient SDS-PAGE gels under reducing conditions and electrotransferred onto Immobilon-P (Millipore Corp.). Western blot analyses were conducted by using rabbit antimouse apoB antisera (1:10,000) or antiglutathione-s-transferase mouse apoB amino acids 26 to 289 17 and an ECL Western blot detection kit (Amersham Pharmacia Biotech, Inc.). The ECL signals were quantified by analyzing the density of the protein bands on x-ray film by by using a Sigma gel computer software (SPPS Science Corp.).
A fast-performance liquid chromatography (FPLC) Superose column was used to assess the distribution of lipids and apoB within the lipoprotein fractions of mouse plasma as described previously. 17, 18 The distribution of apoB in each lipoprotein fraction was determined by Western blot analysis.
Electron Microscopy of Plasma VLDL
Plasma was collected from 20-week-old Apob 38.9/38.9 /Apoe
and Apob ϩ/ϩ /Apoe Ϫ/Ϫ mice after fasting for 4 hours. ␤VLDL (dϽ1.009) was isolated by ultracentrifugation. Negatively stained preparations of VLDL particles were performed as described previously. 30 The stained VLDL particles were examined by using a transmission electron microscope.
Analysis of ApoB-38.9 -and ApoB-48 -VLDL Secreted by Cultured Hepatocytes
Hepatocytes were isolated from 8-to 10-week-old apoE wild-type apoB-38.9 -only or apoB-48 -only mice as described. 17, 18 Viability of the cells (Ϸ80%) was determined by Trypan exclusion.
Cells were plated onto 150-mm dishes (1.5ϫ10 7 cells/dish) coated with poly-D-lysine (Sigma) and incubated at 37°C under 5% CO 2 in 10% fetal bovine serum/DMEM. After 1 to 2 hours of attachment, the cell monolayers were washed twice and incubated in 10% fetal bovine serum/DMEM for 6 hours. Thereafter, cells were washed 3 times with serum-free DMEM. After washing, cells were incubated in 10 mL of DMEM containing 0.5 mmol/L oleic acid complexed with BSA (ratio of oleic acid to BSAϭ3.6:1). 18 Conditioned media were collected after a 6-hour incubation. Media from 4 dishes (ie, a total of 40 mL) from hepatocytes of Apob 38.9/38.9 or Apob 48/48 mice were pooled and adjusted to a density of dϭ1.009 g/mL with KBr and VLDL was isolated by ultracentrifugation. The VLDL fractions were collected and lipids were extracted from the VLDL as described previously. 17, 18, 31 Glycerol tri [1- 14 C] oleate (59.0 Ci/mmol; Amersham Pharmacia Biotech, Inc.) and [1␣, 2␣ (n)-3 H] cholesterol (39.0 Ci/mmol; Amersham Pharmacia Biotech, Inc.) were used as tracers for determination of recovery of lipids. The dried lipid extracts were dissolved in 1% Triton X-100 in chloroform, dried under a stream of N 2 , and then the dried lipid-Trinton X-100 complexes were solubilized in H 2 O as described previously 17, 18, 32 for determination of triglycerides, cholesterol, and phospholipids by using enzymatic kits (WAKO Chemicals USA, Inc.).
Quantification of Aortic Lesion Extent
An en face atherosclerotic lesion measurement technique was used to quantify the lesion extent on unstained, pinned-out aortas. 33, 34 Briefly, after exsanguination, the heart and aorta were perfused with PBS and fixed by perfusion with 4% paraformaldehyde. Thereafter, the aorta was incised longitudinally, dissected free from adventitia, and pinned flat. Images of the pinned aortas were captured by using a Nikon digital camera through a Nikon stereomicroscope and analyzed by using an image processing program. 33, 34 Lesion areas were estimated as percentage of involvement of the intimal surface area for the arch (extending from the aortic valve to a point just distal to the left subclavian artery), the thoracic aorta (extending to the last intercostal artery), and the abdominal aorta (extending to the ileal bifurcation).
Miscellaneous Procedures
Cellular protein contents were determined by using a modified Lowry method. 35 Plasma lipids were determined by using enzymatic kits (WAKO Chemicals USA, Inc.).
Results
Production of ApoB-38-9 -Only/apoE-Null Mice
ApoB-38.9 is present at a much lower level than apoB-48 in the apoB-38.9 -heterozygous mice because of its faster clearance rate. 17, 18 However, we have previously 18 shown that deletion of the Apoe in apoB-38.9 -heterozygous (Apob ϩ/38.9 ) mice retarded catabolism of the apoB-38.9 -containing lipoproteins. Thus, we anticipated that disruption of Apoe in apoB-38.9 -only (Apob 38.9/38.9 ) mice would cause accumulation of apoB-38.9 -containing lipoproteins in plasma and would allow us to examine their physicochemical characteristics and atherogenicity in vivo. mice on apoE wild-type background, which is only 50% lower than expected. 17, 18 The mechanism underlying the diminished survival rates of the Apob 38.9/38.9 /Apoe Ϫ/Ϫ embryo remains to be understood. Nevertheless, all of the 5 Apob 38.9/38.9 / Apoe Ϫ/Ϫ mice survived to adulthood and appeared healthy, but one died at the age of 9 months for unknown reasons.
Evidence for the Ability of ApoB-38.9 to Form Cholesterol-Rich Lipoproteins
As shown by Figure 1, (Figure 2) . This is in sharp contrast to the distribution of apoB-38.9 in plasma of Apob 38.9/38.9 /Apoe ϩ/ϩ and Apob ϩ/38.9 / Apoe ϩ/ϩ mice, in which apoB-38.9 was eluted only as LDL-HDL-sized particles (fractions 22 to 32; Figure 2 , panel D and the references 17, 18 ). On negative-staining electron microscopy, the apoB-38.9 -␤VLDL particles from the Apob 38.9/38.9 /Apoe Ϫ/Ϫ mice appeared very heterogenous in size, with particle diameters ranging from 10 to 200 nm. The median diameter of these apoB-38.9 -␤VLDL particles was approximately 45 nm, which is similar in size to apoB-48 -␤VLDL particles. The negatively stained apoB-38.9 -␤VLDL and apoB-48 -␤VLDL particles appeared to be spherical and similar in shape. Chemical analysis of apoB-38.9 -␤VLDL particles revealed that they were relatively more enriched with cholesteryl esters but triglyceride-poor than the apoB-48 -␤VLDL particles (ratios of cholesteryl ester to triglyceride: 23 for apoB-38.9 -␤VLDL versus 15 for apoB-48 -␤VLDL).
Mouse plasma has very little cholesteryl ester-transfer protein activity, 36 which is responsible for transferring cholesteryl esters from HDLs to LDLs in humans. 37 Thus, the presence of the cholesterol-rich apoB-38.9 -␤VLDL in Apob 38.9/38.9 /Apoe Ϫ/Ϫ mouse plasma suggests that apoB-38.9 may be capable of assembling cholesterol-rich VLDLs in the /Apoe Ϫ/Ϫ had a mixed genetic background with 75% C57BL/6 and 25% 129/SvJ. Figure 1 . Plasma cholesterol and apoB levels in apoB-38.9 mice on apoE-wild-type or apoE-null background. Plasma was sampled from 20-week-old mice after fasting for 4 hours. The values of plasma cholesterol represent the average and standard error of 4 mice. Aliquots of plasma pooled from 4 mice of each genotype were subjected to Western blot as described in the Methods section.
liver and intestine. To examine this possibility, VLDLs (dϽ1.009 g/mL) were isolated from conditioned media from cultured apoB-48 -only or apoB-38.9 -only hepatocytes and analyzed for lipid composition. As shown in Table 2 , the apoB-38.9 -VLDL was relatively triglyceride poor but cholesterol rich compared with apoB-48-VLDL.
Together, these results demonstrate that despite its impaired capability to transport triglycerides, apoB-38.9 has a relatively intact ability to transport cholesterol. This finding suggests that distinct domains on the apoB protein may be responsible for recruiting triglycerides and cholesterol into apoB-lipoproteins during VLDL assembly.
Atherogenic Potential of ApoB-38.9 -Containing Lipoproteins
To determine whether apoB-38.9 is capable of supporting atherogenesis, spontaneous aortic lesion extent was measured in the 4 Apob (Figure 3, panels B and C) . Plasma levels of apoA-I and apoA-IV were not affected by the apoB-38.9 mutation in the apoE-null mice (Figure 4) , indicating that the atherosclerotic development in the Apob 38.9/38.9 /Apoe Ϫ/Ϫ mice was caused by accumulation of atherogenic lipoproteins rather than by reduced levels of antiatherogenic agents, such as apoA-I 38,39 and apoA-IV. 40, 41 Collectively, these results established direct evidence demonstrating the atherogenicity of apoB-38.9 -containing lipoproteins.
Discussion
ApoB is a major atherogenic apolipoprotein in humans and experimental animal models. [3] [4] [5] The atherogenicity of apoB may be dependent on the ability of apoB to carry cholesterol and on its susceptibility to retention in the subendothelial space and the subsequent oxidative modification and uptake by macrophages in the vessel wall. 4, [42] [43] [44] Current understanding of the structurefunction relationship of apoB with respect to these atherogenic processes is still incomplete. It has been shown that apoB-48 -containing lipoproteins are as atherogenic as the apoB-100 -containing lipoproteins, 27 indicating that the "atherogenic domains" of apoB-100 may be located within the N-terminal 48% of apoB-100. We now provide in vivo evidence that apoB-38.9, the N-terminal 38.9% of apoB-100, is fully atherogenic, thus narrowing the "atherogenic region" of apoB.
By using our previously generated apoB-38.9 mice bred onto an apoE-null background, we for the first time demonstrated that apoB-38.9 is capable of forming cholesterol-rich ␤VLDL-like lipoprotein particles in mouse plasma. We also showed that apoB-38.9 -VLDL secreted by cultured Apob 38.9/38.9 hepatocytes was relatively triglyceride poor but cholesterol rich compared with the apoB-48-VLDL secreted by the Apob 38.9/38.9 hepatocytes. We have previously shown that apoB-38.9 has a much smaller capability for triglyceride transport than apoB-48. 17 The apoB-38.9 -specifying mutation caused accumulation of triglycerides but not cholesterol or cholesteryl esters in the liver of the mutant mice, 17 further suggesting that apoB-38.9 may have a normal capacity for hepatic cholesterol export via VLDL secretion. Thus, C-terminal truncation of apoB appears to exert differential effects on its ability to transport triglycerides and cholesterol, implying that distinct peptide regions within apoB-48 may be responsible for transporting different lipid classes. In contrast with apoB-38.9, apoB-27.6 is incapable of assembling buoyant lipoprotein particles. 18 Furthermore, disruption of apoE gene did not cause accumu- VLDL was isolated from media of apoB-48 -only or apoB-38.9 -only hepatocytes after being cultured for 6 hours in serum-free DMEM containing 0.5 mmol/L oleic acids. Each value represents the mean of two independent experiments. lation of plasma of apoB-27.6 -lipoproteins in the apoB-27.6 mice, 18 nor did it alter the density distribution of apoB-27.6 -lipoproteins in the plasma (data not shown). Taken together, these observations suggest that the peptide region between COOH termini of apoB-27.6 and apoB-38.9 may have specific roles in cholesterol transport whereas the region between the COOH-termini of apoB-38.9 and apoB-48 may be more important for triglyceride transport. Compared with the nascent apoB-48 -or apoB-38.9 -containing VLDL particles found in the media of cultured hepatocytes, plasma apoB-48 -or apoB-38.9 -containing ␤VLDL particles circulating in the apoE-deficient mice contain much more cholesteryl esters and less unesterified cholesterol (data not shown). HDL is not a source of cholesterol esters for plasma apoB-containing lipoproteins in mouse because mouse plasma does not have cholesteryl ester transfer protein. 36 However, a recent study has shown that lecithin-cholesterol acyltransferase plays an important role in esterification of the cholesterol associated with apoB48-VLDL in mouse plasma. 45 Thus, significant amounts of cholesteryl esters in the apoB-38.9 -␤VLDL of our mice may be formed in plasma via lecithin-cholesterol acyltransferase catalyzed esterification of cholesterol found in the nascent apoB-38.9 -VLDL particles.
The assembly of VLDL and chylomicrons is a complex process that brings together the amphipathic apoB polypeptide and 4 different classes of lipids, including surface lipid components (phospholipids and unesterified cholesterol) and a neutral lipid core composed of triglycerides and cholesterol esters. It is not known how the apoB-27.6 -apoB-38.9 and the apoB-38.9 -apoB-48 peptide segments exert their specific roles in cholesterol and triglyceride recruitment. It has been suggested that VLDL assembly undergoes a 2-step process, 10,46,47 with a majority of triglycerides being recruited in the second step. 46, 47 It is possible that the apoB-38.9 -apoB-48 peptide segment is particularly important for recruiting triglycerides during the second step of VLDL biogenesis whereas apoB-27.6 -apoB-38.9 segment is sufficient for cholesterol/cholesteryl ester recruitment. A previous study by McLeod et al 48 demonstrated that several ␤-sheet regions within the human apoB-27-apoB-48 were capable of assembling VLDL particles when they were fused to apoAI at the C-terminus, indicating that these apoB peptide segments are important for the lipid recruitment during the second step of /Apoe Ϫ/Ϫ mice. All of these mice had a mixed genetic background of 75% C57BL/6 and 25% 129/SvJ. Lesion area was determined in mice at age 9 months (A) and 13 months (B and C) and expressed as percent of the total surface area of each aortic segment. The average plasma cholesterol levels of each group of mice are shown in the text boxes. Images of representative unstained, pinned out aortas are shown in C, with an aorta from a wild-type (Apob ϩ/ϩ /Apoe ϩ/ϩ ) mouse as a negative control.
VLDL formation. Further studies are required to determine the specificity of different apoB peptide regions in recruiting different lipid classes for VLDL formation.
Extensive aortic atherosclerotic lesions were seen in all of the four Apob 38.9/38.9
/Apoe
Ϫ/Ϫ mice that we studied. The lesions in these mice were as large as those of their Apob ϩ/38.9
Ϫ/Ϫ or Apob ϩ/ϩ /Apoe Ϫ/Ϫ littermates. This finding demonstrates the atherogenic potential of apoB-38.9 -containing lipoproteins. It is unlikely that susceptibilities to atherosclerotic development of these mice differed. They all had a mixed genetic background of 75% C57BL/6 and 25% 129/SvJ. High plasma levels of apoBcontaining lipoproteins result in atherosclerotic lesions in other mouse models with a similar genetic background. For example, lesions are evident in apoE-null/apoB-48 -only and apoE-null/ apoB-100 -only mice with a mixed genetic background of 75% C57BL/6 and 25% 129/SvJ, 27 the same as our study. Furthermore, plasma levels of two major antiatherogenic apoproteins, apoA-I and apoA-IV, were very similar in the Apob 
Ϫ/Ϫ , and Apob ϩ/38.9 /Apoe Ϫ/Ϫ mice. Thus, the aortic lesions developed in our Apob 38.9/38.9 /Apoe Ϫ/Ϫ mice were unlikely because of a peculiarly increased susceptibility of the "host" artery to lesion formation. It is more likely that the high levels of apoB-38.9 -containing lipoproteins in these mice were responsible. Because of the limited number of Apob 38.9/38.9 /Apoe Ϫ/Ϫ mice that were available to this study, we were not able to determine the potential difference in the atherogenicity of apoB-38.9 -and apoB-48 -containing lipoproteins.
Currently, it is not clear what intrinsic structure within the apoB protein is essential for the atherogenicity of apoBlipoproteins, but it is generally thought that the proteoglycanbinding function of apoB may have an important role [42] [43] [44] because interactions between apoB on the lipoprotein particle and arterial proteoglycans may lead to subendothelial retention of apoB lipoproteins, 24 ,43 a critical step in early atherosclerosis. 24 , 43 We found that although the length of apoB-38.9 is 20% less than that of apoB-48, the apoB-38.9 -containing lipoproteins bound heparin and biglycans with affinities similar to or even higher than those of apoB-48 -␤VLDL (Z. Chen, unpublished data). Thus, the NH 2 -terminal 38.9% of apoB-100 may be sufficient to mediate subendothelial retention of the apoBcontaining lipoproteins. In fact, it was recently shown that the principal proteoglycan-binding site of human apoB-48 -lipoproteins may be located within the first 100 residues of apoB. 49 This apoB peptide segment is also involved in interactions of human apoB-100-LDL with proteglycans. 50 The putative proteoglycanbinding motifs in this region are conserved between human and mouse apoB proteins (Z. Chen, unpublished data). Thus, the principal proteoglycan-binding site of mouse apoB-38.9-and apoB-48-containing lipoproteins may also be located within the NH 2 terminal 100 residues. Another important aspect of the atherogenic process is the uptake of the native and/or oxidized apoBlipoproteins by macrophages in the arterial wall. 4, 42, 51 Recent studies suggest that the oxidized phospholipids of oxidized apoBlipoproteins play important roles in mediating the uptake of these apoB-lipoproteins by macrophages via scavenger receptors. [52] [53] [54] [55] The role of apoB in this process is poorly understood. However, if any specific apoB structural domain(s) is required for this process, apoB-38.9 apparently contains such domain(s). , and Apob 38.9/38.9
mice. Plasma was sampled from mice after fasting for 4 hours and subjected to Western blot analysis by using rabbit antimouse apoA-I or antimouse apoA-IV antisera. Each lane was loaded with 2 L of plasma. ECL signals were quantified as described in the Experimental Procedures section.
